Neoadjuvant Inetetamab Combined With Pertuzumab and Paclitaxel/Carboplatin for Breast Cancer
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
Inetetamab (Cipterbin) is a newly marketed anti-HER2 monoclonal antibody with amino acid
modified Fc region and enhanced antibody-dependent cellular cytotoxicity (ADCC) effect. There
was no robust evidence evaluating the combination of inetetamab with pertuzumab and
neoadjuvant chemotherapy (paclitaxel + carboplatin) in the neoadjuvant setting. This study
aimed to evaluate the efficacy and safety of inetetamab + pertuzumab+paclitaxel + carboplatin
(TCbIP) as a neoadjuvant chemotherapy regimen in the treatment of patients with locally
advanced HER2-positive breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences